Amgen (AMGN) Short term Debt (2009 - 2026)

Amgen has reported Short term Debt for 16 years, with the latest figure at $5.4 billion in Q2 2026.

• On a quarterly basis, Short term Debt rose 122.79% year-over-year to $5.4 billion in Q2 2026; TTM through Jun 2026 was $5.4 billion, a 122.79% increase from a year earlier, with the FY2025 full-year figure at $4.6 billion, up 29.55% from the prior year.
• Short term Debt was $5.4 billion for Q2 2026 at Amgen, roughly flat from $5.4 billion in the prior quarter.
• The five-year high for Short term Debt was $5.5 billion in Q2 2024, with the low at $817.0 million in Q2 2022.
• Average Short term Debt over 5 years is $2.8 billion, with a median of $2.3 billion recorded in 2023.
• The largest YoY upside for Short term Debt was 1728.74% in 2022 against a maximum downside of 81.11% in 2022.
• Over 5 years, Short term Debt stood at $1.6 billion in 2022, then slipped by 9.3% to $1.4 billion in 2023, then jumped by 146.02% to $3.6 billion in 2024, then rose by 29.55% to $4.6 billion in 2025, then climbed by 18.4% to $5.4 billion in 2026.
• The last three Short term Debt figures came in at $5.4 billion (Q2 2026), $5.4 billion (Q1 2026), and $4.6 billion (Q4 2025), per Business Quant data.